BIOMAT Database Logo BIOMAT Database Logo

[Immunosuppressive therapy in primary chronic polyarthritis]. 1972

H Warnatz

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine

Related Publications

H Warnatz
[Immunosuppressive therapy chronic polyarthritis].
December 1972, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,
H Warnatz
[Immunosuppressive therapy of progredient chronic polyarthritis].
February 1974, MMW, Munchener medizinische Wochenschrift,
H Warnatz
[Immunosuppressive therapy of primary chronic polyarthritis and systemic lupus erythematodes disseminatus].
September 1971, Die Medizinische Welt,
H Warnatz
[Primary immune reactions in patients with chronic polyarthritis under cytostatic ("immunosuppressive") therapy].
January 1972, Zeitschrift fur Rheumaforschung,
H Warnatz
[Immunosuppressive therapy in polyarthritis].
April 1972, Medizinische Monatsschrift,
H Warnatz
[Therapy of primary chronic polyarthritis using the immunosuppressive, cytostatically active podophyllin derivative, Proresid].
April 1973, Die Medizinische Welt,
H Warnatz
[Evaluation of immunosuppressive therapy with podophyllin derivatives in the treatment of primary chronic polyarthritis].
January 1969, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
H Warnatz
[Evaluation of immunosuppressive therapy with podophyllin derivatives in the treatment of primary chronic polyarthritis].
May 1969, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
H Warnatz
[THERAPY OF PRIMARY CHRONIC POLYARTHRITIS].
August 1964, Deutsches medizinisches Journal,
H Warnatz
[Echinacin in primary chronic polyarthritis therapy].
April 1981, ZFA. Zeitschrift fur Allgemeinmedizin,
Copied contents to your clipboard!